Quince Therapeutics Inc. Common Stock (QNCX)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-and-Graham-style investor, I begin with business quality and earnings power. Quince Therapeutics is a 38-employee biotech with a Phase 3 asset, eDSP, and no reported revenue in the filed figures I was given. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported a net loss of $75.5 million and diluted EPS of -$12.31; in fiscal Q1 2026, the quarter ended 2026-03-31, it reported net income of $35.9 million and diluted EPS of $2.88, so the quarterly pattern is erratic. For FY2025, ended 2025-12-31, net loss was $84.0 million and diluted EPS was -$1.68; FY2024, ended 2024-12-31, lost $56.8 million, and FY2023, ended 2023-12-31, lost $31.4 million. The FairStock Lynch category is none because the company lost money in each of the last four years. I see no durable competitive moat: no revenue, no profits, and a clinical-stage drug/device platform. Financial health is poor by the given FairStock calculations: Piotroski F-Score 1/9, Altman Z-Score -4.43, ROE -153.84%, ROCE -31.51%, and trailing free cash flow of -$47.0 million, which is a -165.8% FCF yield on the $28.3 million market cap. Debt-to-equity is low at 0.02, but that does not offset persistent losses. At the 2026-10-13 close of $27.87, FairStock shows a negative P/E of -0.13. Valuation is not anchored to earnings, book value, or cash generation; it is a speculative option on clinical success. Growth is unproven without revenue, and the 52-week range of $0.79 to $45.50 shows extreme volatility. I find no margin of safety in the numbers provided.

In plain English: Quince Therapeutics is a small medical research company working on treatments for rare diseases, including a late-stage program for a rare childhood neurodegenerative condition. The business looks weak today: the filed figures show no revenue and repeated losses, and its cash flow is negative. At the 2026-10-13 closing price of $27.87, the price looks expensive relative to those numbers because there are no profits or sales to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer